Grifols Acquires Remaining 56% of GigaGen for ~$80M

 Grifols Acquires Remaining 56% of GigaGen for ~$80M

Grifols Acquires Remaining 56% of GigaGen for ~$80M

Shots:

  • Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost Grifol’s portfolio if I-O therapies
  • Earlier, in 2017, Grifols acquired a 44% stake in GigaGen, when the two companies collaborated to develop polyclonal antibodies under a $50M pact
  • GIGA-2050 is expected to be evaluated in P- I trial in the US in spring 2021, following the IND approval

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Yicai Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post